Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry

摘要

Renal impairment (RI) is common in patients with multiple myeloma (MM) and is associated with poor prognosis. The Australia and New Zealand Myeloma Registry was used to assess > 1000 newly diagnosed MM patients, of whom 383 had RI at diagnosis. Patients who underwent autologous stem cell transplantation (ASCT) despite RI had improved survival; potential factors for an inferior outcome include suboptimal use of bortezomib and ASCT.